Thomas Patrick Kelly
Chief Financial OfficerMr. Thomas Patrick Kelly, JD, also known as Tucker, is Chief Financial Officer of Xenon Pharmaceuticals Inc. from October 2025. He had been the Executive Vice President and Treasurer at Deciphera Pharmaceuticals, Inc. since January 2019 and serves as Chief Financial Officer of Deciphera Pharmaceuticals, Inc. since February 2015. Mr. Kelly has years of financial leadership and strategic management experience. Mr. Kelly serves as Executive Vice President and Treasurer at Deciphera Pharmaceuticals Inc since March 2019. He served as Chief Financial Officer of AdvanDx, Inc from 2012 to 2014. Mr. Kelly joined AdvanDx in 2012 and has years of experience building life sciences and biotechnology companies. He has held positions as a Chief Financial Officer for both public and private companies as well as a life sciences investment banker and a corporate and securities attorney. Prior to joining AdvanDx, Mr. Kelly served as the Chief Financial Officer of deCODE genetics, a leading genetics research company from 2010 to 2011. He was a Principal of Canaccord Adams. Mr. Kelly served as Chief Financial Officer and Senior Vice President of Finance & Corporate Development of Chiesi USA, Inc. (Alternate Name, Cornerstone Therapeutics Inc. and Critical Therapeutics Inc.) from August 20, 2007 to October 31, 2008. He was a Principal of Canaccord Genuity Inc. He joined Adams Harkness (merged into Canaccord Adams in January 2006) as part of the Healthcare Group in 2003 and was responsible for the Emerging Therapeutics banking efforts. He has been life sciences investment banker since 1998. Mr. Kelly served as Vice President of Life Sciences Investment Banking of Robertson Stephens & Co., L.L.C. in both Boston and London. Before his tenure in investment banking, Mr. Kelly served as a Corporate and Securities Attorney of Foley, Hoag & Eliot, LLP. During his career, he has advised public and private life science clients in the United States and in Europe on their corporate finance and capital markets activities on more than 50 financing and advisory transactions. He has an extensive experience in financing and strategic transactions for life science and other growth companies, having completed more than 30 transactions. He is also a Massachusetts Bar Association Member. Mr. Kelly received a Bachelor of Science in Foreign Service from Georgetown University School of Foreign Service and a Juris Doctorate from the University of Chicago Law School.
Positions
- Company NameXenon Pharmaceuticals Inc.Stock CodeXENEPositionChief Financial OfficerColleagues
- ICIan C. MortimerPresident, CEO & Director
- DADawn A. SvoronosIndependent Chairman
- ADAndrea DiFabioChief Legal Officer & Corporate Secretary
- CJChristopher John KenneyChief Medical Officer
- DSDarren S. ClineChief Commercial Officer
- SRSteven R. GannonIndependent Director
- JDJustin D. GoverIndependent Director
- GPGary PatouIndependent Director
